• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·EVERESTO.BO
Share

Everest Organics Limited Stocks

₹ 288.75Last Updated 28.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

₹ 29.21M

₹ 288.75
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Everest Organics Limited is a pharmaceutical enterprise specializing in the production of bulk drugs. Its product line encompasses compounds such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, and Benzimadizole. Additionally, the company manufactures and exports active pharmaceutical ingredients (APIs) and their intermediates from its facilities in India, supplying these to formulation companies worldwide. The firm was founded on February 19, 1993, and its headquarters are located in Hyderabad, India.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.07.2026 10:50

Top Stories This Morning: U.S. Strikes Iran, AI Helps Samsung, EU to Tighten Oversight of ChatGPT

30.07.2026 09:00

Airbus's profits exceeded expectations amid an increase in aircraft deliveries

30.07.2026 08:00

Citi recommended buying Ford shares following the earnings report. Why does the bank expect them to rise by 33%?

30.07.2026 02:31

The Nasdaq 100 Index closed the trading session in correction territory

30.07.2026 02:03

Microsoft Shares Rise After Earnings Report: Cloud Business Posts Best Growth Since 2022

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026